Roxee Meds Catalog

Maropitant Citrate

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet Multiple FDA sponsors Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts

Catalog refreshed

May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
The storefront fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 7:40 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Maropitant Citrate Tablets · official_label
openFDA case USA-USFDACVM-2025-US-070810 · adverse_reaction

Image coming soon

Maropitant Citrate

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Maropitant Citrate

Antiemetic used to prevent and treat vomiting (and motion sickness in dogs). Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name

Maropitant Citrate

Brand names

Cerenia® Tablets, Cerenia® Injectable Solution, Maropitant Citrate, Maropitant Citrate Tablets

Manufacturer

Multiple FDA sponsors

Species

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Dosage forms

Tablet, Liquid (Solution), Injectable Solution, Chewable Tablets

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Cerenia® Tablets Cerenia® Injectable Solution Maropitant Citrate Maropitant Citrate Tablets

Dosage forms

Tablet Liquid (Solution) Injectable Solution Chewable Tablets

Indications / Uses

Antiemetic used to prevent and treat vomiting (and motion sickness in dogs).

Administration / How To Give

Oral / Injectable

Storage

Store per label; protect injectable from light.

Warnings / Contraindications

Use caution with severe liver disease.

Use caution with severe liver disease.

Side Effects

Pain at injection site, lethargy, diarrhea.

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet, Liquid (Solution), Injectable Solution, Chewable Tablets

Store per label; protect injectable from light.

Related Medications

Related Conditions

Acute vomiting Gastrointestinal (additional)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: /static/meds/images/maropitant_citrate.jpg
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/817
Last refreshed: May 5, 2026, 10:00 a.m.
Last verified: Feb 12, 2026, 7:40 p.m.
Validation status: Complete

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Use caution with severe liver disease
wobbly/unsteady walking (1 reports)
Loss of appetite (1 reports)
Bladder distension (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Major cautions & emergency warning signs

Side effects to monitor:

Use caution with severe liver disease
wobbly/unsteady walking
Loss of appetite
Bladder distension

Most reported reactions:

Unsteady walking (ataxia) (1 reports)
Loss of appetite (1 reports)
Bladder distension (1 reports)

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA sponsors

Form: Chewable Tablets, Injectable Solution, Liquid (Solution), Tablet

Identifiers:

ANADA: 200710 ANADA: 200747 ANADA: 200785 ANADA: 200833 NADA: 141262 NADA: 141263 NDC Package: 11695-7029-1 NDC Package: 11695-7029-2 NDC Package: 11695-7030-1 NDC Package: 11695-7030-2 NDC Package: 11695-7031-1 NDC Package: 11695-7031-2 NDC Package: 11695-7032-1 NDC Package: 11695-7032-2 NDC Package: 11695-7054-1 NDC Package: 11695-7054-2 NDC Package: 11695-7055-1 NDC Package: 11695-7055-2 NDC Package: 11695-7056-1 NDC Package: 11695-7056-2

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200833 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200710 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Use caution with severe liver disease.

High: Use caution with severe liver disease.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (1) · Loss of appetite Skin & allergy (2) · Hair loss at application site, Application site hair loss Neurologic (1) · Unsteady walking (ataxia) Behavior (3) · Biting -aggression, Behavioral disorder (unspecified), Anxiety Other (25) · Bladder distension, Bilirubinuria, Basophilia

Most Reported Reactions

Body system	Cases	Species	Serious cases
Neurologic	1	Cat	1
Digestive	1	Dog	1
Other	1	Cat	1
Behavior	1	Dog	1
Behavior	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Cat	1

Species coverage: Dog (19) Cat (13)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Neurologic	Cat	Serious	-	1
Digestive	Dog	Serious	-	1
Skin & allergy	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Behavior	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Behavior	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Skin & allergy	Cat	Non-serious	-	1
Other	Cat	Non-serious	-	1
Behavior	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-070810

Storage & Handling

Store per label; protect injectable from light.

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

No owner handouts linked yet.

Official label / PI

No official label or package insert links yet.

SPL

FOI

Maropitant Citrate Tablets

SPL · SPL

Open original

FDA Structured Product Label

Maropitant Citrate Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-833
Status: RX
Form: Chewable Tablets
Route: Oral

Composition / specifications

16 mg, 24 mg, 60 mg, or 160 mg of maropitant as maropitant citrate per tablet

Dogs

Indication

For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Dosage

For Prevention of Acute Vomiting in dogs 2 - 7 months of age: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.

Maropitant Citrate

SPL · SPL

Open original

FDA Structured Product Label

Maropitant Citrate

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Dechra Veterinary Products LLC
ANADA: 200-710
Status: RX
Form: Injectable Solution
Route: Intravenous, Subcutaneous

Composition / specifications

Each mL contains 10 mg of maropitant as maropitant citrate

Dogs

Indication

For the prevention and treatment of acute vomiting.

Dosage

Administer 1.0 mg per kilogram (mg/kg) of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.

Cats

Indication

For the treatment of vomiting.

Dosage

Administer 1.0 mg/kg of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.

Maropitant Citrate Tablets

SPL · SPL

Open original

FDA Structured Product Label

Maropitant Citrate Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-785
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

16 mg, 24 mg, 60 mg, or 160 mg of maropitant citrate per tablet

Dogs

Indication

For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Dosage

For Prevention of Acute Vomiting in dogs 2 -7 months of age: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.

For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.

Maropitant Citrate

SPL · SPL

Open original

FDA Structured Product Label

Maropitant Citrate

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: ZYVET AH, Inc.
ANADA: 200-747
Status: RX
Form: Tablet
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

16, 24, 60, or 160 mg of maropitant as maropitant citrate per tablet

Dogs (2-7 months of age)

Indication

For prevention of acute vomiting.

Dosage

Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.

Dogs (7 months of age and older)

Indication

For prevention of acute vomiting.

Dosage

Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Dogs (4 months of age and older)

Indication

For prevention of vomiting due to motion sickness.

Dosage

Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.

Cerenia® Tablets

SPL · SPL

Open original

FDA Structured Product Label

Cerenia® Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-262
Status: RX
Form: Tablet
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each tablet contains 16, 24, 60, or 160 milligrams (mg) maropitant as maropitant citrate.

Dogs (7 Months of Age and Older)

Indication

For the prevention of acute vomiting.

Dosage

Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Limitations

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs (4 Months of Age and Older)

Indication

For the prevention of vomiting due to motion sickness.

Dosage

Administer CERENIA Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days

Limitations

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. CERENIA injectable solution should not be used interchangeably with CERENIA tablets for the prevention of vomiting due to motion sickness (8mg/kg).

Dogs (2-7 Months)

Indication

For the prevention of acute vomiting.

Dosage

Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days

Limitations

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cerenia® Injectable Solution

SPL · SPL

Open original

FDA Structured Product Label

Cerenia® Injectable Solution

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-263
Status: RX
Form: Liquid (Solution)
Route: Subcutaneous, Intravenous
Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains 10 milligrams (mg) maropitant as maropitant citrate.

Dogs (2-4 Months of Age)

Indication

For Prevention and Treatment of Acute Vomiting in Dogs: Dogs 2-4 Months of Age:

Dosage

Administer subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/kg (0.1 mL/2.2 lb) of body weight once daily for up to 5 consecutive days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Dogs (4 Months of Age and Older)

Indication

For Prevention of Vomiting in Dogs 4 months of Age and Older Caused by Emetogenic Medications or Chemotherapeutic Agents.

Dosage

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) of body weight one time, 45-60 minutes prior to use of emetogenic medications or chemotherapeutic agents.

Limitations

Indication

For Prevention and Treatment of Acute Vomiting in Dogs: Dogs 2-4 Months of Age:

Dosage

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/1 kg (1 mL/22 lb) of body weight once daily for up to 5 consecutive days.

Limitations

Cats (4 Months of Age and Older)

Indication

For Treatment of Vomiting in Cats 4 Months of Age and Older

Dosage

FOI · FOI

Open original

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17886 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18228/Maropitant%20Citrate%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17776 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18133/Maropitant%20Citrate · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15545 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15805/Maropitant%20Citrate%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13695 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13897/Maropitant%20Citrate · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/817 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/816 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
The storefront fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Official (FDA)

Identity: Generic ingredient • No FDA branded products linked

No official FDA brand rows linked yet for this ingredient.

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog

Rx/OTC: RX

Form/route: Chewable Tablets, Injectable Solution, Liquid (Solution), Tablet • Intravenous, Oral, Subcutaneous

Applications: ANADA 200-833 • ANADA 200-710 • ANADA 200-785 • ANADA 200-747 • NADA 141-262 • NADA 141-263

Documents: 10 (FOI: 10) • SPL: 6 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 261 • Cat 195 • View

Case summaries: 89 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Acute vomiting Gastrointestinal (additional)

Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Use caution with severe liver disease. (Contraindication, High)

Top reaction signals

Unsteady walking (ataxia) (1) Loss of appetite (1) Bladder distension (1) Biting -aggression (1) Behavioral disorder (unspecified) (1) Basophilia (1) Azotaemia (1) Ascites (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
11695-7029-1	11695	-
11695-7029-2	11695	-
11695-7030-1	11695	-
11695-7030-2	11695	-
11695-7031-1	11695	-
11695-7031-2	11695	-
11695-7032-1	11695	-
11695-7032-2	11695	-
11695-7054-1	11695	-
11695-7054-2	11695	-
11695-7055-1	11695	-
11695-7055-2	11695	-
11695-7056-1	11695	-
11695-7056-2	11695	-
11695-7057-1	11695	-
11695-7057-2	11695	-
13612-0035-0	13612	-
13612-0035-1	13612	-
17033-004-01	17033	-
17033-006-04	17033	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

FOI Summary oA 200-833 Approved January 12, 2026.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 200833
FOI Summary oA 200-710 Approved December 5, 2025.pdf • FOI summary • Official • Jan. 5, 2026
FDA FOI summary for application 200710
FOI Summary oA 200-785 Approved June 17, 2024.pdf • FOI summary • Official • July 1, 2024
FDA FOI summary for application 200785
FOI Summary oA 200-747 Approved March 31, 2023.pdf • FOI summary • Official • March 31, 2023
FDA FOI summary for application 200747
UCM050060.pdf • FOI summary • Official • Jan. 31, 2019
FDA FOI summary for application 141262
UCM453543.pdf • FOI summary • Official • Jan. 31, 2019
FDA FOI summary for application 141262
ucm062313.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141263
UCM314825.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141263
UCM314823.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141263
UCM484493.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141263

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 25 Clinical 9 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: Use caution with severe liver disease. (Clinical, 2026-02-12)
overdose_info: Overdose causes excessive drooling, lethargy, collapse due to low BP. Emergency care includes IV fluids, blood pressure support, and monitoring. (Clinical, 2026-04-12)
overdose_info: Overdose causes excessive drooling, lethargy, collapse due to low BP. Emergency care includes IV fluids, blood pressure support, and monitoring. (Clinical, 2026-04-11)
overdose_info: Overdose causes excessive drooling, lethargy, collapse due to low BP. Emergency care includes IV fluids, blood pressure support, and monitoring. (Clinical, 2026-02-12)
side_effects: Pain at injection site, lethargy, diarrhea. (Clinical, 2026-04-11)
storage_handling: Store per label; protect injectable from light. (Clinical, 2026-04-12)
storage_handling: Store per label; protect injectable from light. (Clinical, 2026-04-11)
storage_handling: Store per label; protect injectable from light. (Clinical, 2026-02-12)
usage: Antiemetic used to prevent and treat vomiting (and motion sickness in dogs). (Clinical, 2026-02-12)
contraindications: Use caution with severe liver disease. (Official, 2026-04-12)
contraindications: Use caution with severe liver disease. (Official, 2026-04-11)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-05-05)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-05-03)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-05-02)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-04-29)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-04-28)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-04-27)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-04-26)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-04-25)
indications: Dogs:Â For the prevention and treatment of acute vomiting.Cats:Â For the treatment of vomiting. For the prevention and treatment of acute vomiting in dogs. For… (Official, 2026-04-22)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Maropitant Citrate Tablets RX Maropitant Chewable Tablets • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-833	Approved	Feb 2, 2026
Maropitant Citrate RX Maropitant Injectable Solution • Intravenous, Subcutaneous Label highlights Official documents	Dechra Veterinary Products LLC	ANADA 200-710	Approved	Jan 5, 2026
Maropitant Citrate Tablets RX Maropitant Tablet • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-785	Approved	Jul 1, 2024
Maropitant Citrate RX Maropitant Tablet • Oral Label highlights Official documents	ZYVET AH, Inc.	ANADA 200-747	Approved	Mar 31, 2023
Cerenia® Tablets RX Maropitant Tablet • Oral Label highlights Official documents	Zoetis Inc.	NADA 141-262	Approved	Jan 31, 2019
Cerenia® Injectable Solution RX Maropitant Liquid (Solution) • Subcutaneous, Intravenous Label highlights Official documents	Zoetis Inc.	NADA 141-263	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

16 mg, 24 mg, 60 mg, or 160 mg of maropitant as maropitant citrate per tablet

Dogs

Indication

For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

Each mL contains 10 mg of maropitant as maropitant citrate

Dogs

Indication

For the prevention and treatment of acute vomiting.

Dosage

Administer 1.0 mg per kilogram (mg/kg) of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.

Limitations

Cats

Indication

For the treatment of vomiting.

Dosage

Administer 1.0 mg/kg of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

16 mg, 24 mg, 60 mg, or 160 mg of maropitant citrate per tablet

Dogs

Indication

For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Dosage

For Prevention of Acute Vomiting in dogs 2 -7 months of age: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.

For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

16, 24, 60, or 160 mg of maropitant as maropitant citrate per tablet

Dogs (2-7 months of age)

Indication

For prevention of acute vomiting.

Dosage

Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.

Limitations

Dogs (7 months of age and older)

Indication

For prevention of acute vomiting.

Dosage

Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Limitations

Dogs (4 months of age and older)

Indication

For prevention of vomiting due to motion sickness.

Dosage

Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each tablet contains 16, 24, 60, or 160 milligrams (mg) maropitant as maropitant citrate.

Dogs (7 Months of Age and Older)

Indication

For the prevention of acute vomiting.

Dosage

Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Limitations

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs (4 Months of Age and Older)

Indication

For the prevention of vomiting due to motion sickness.

Dosage

Administer CERENIA Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days

Limitations

Dogs (2-7 Months)

Indication

For the prevention of acute vomiting.

Dosage

Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days

Limitations

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains 10 milligrams (mg) maropitant as maropitant citrate.

Dogs (2-4 Months of Age)

Indication

For Prevention and Treatment of Acute Vomiting in Dogs: Dogs 2-4 Months of Age:

Dosage

Administer subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/kg (0.1 mL/2.2 lb) of body weight once daily for up to 5 consecutive days.

Limitations

Dogs (4 Months of Age and Older)

Indication

For Prevention of Vomiting in Dogs 4 months of Age and Older Caused by Emetogenic Medications or Chemotherapeutic Agents.

Dosage

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) of body weight one time, 45-60 minutes prior to use of emetogenic medications or chemotherapeutic agents.

Limitations

Indication

For Prevention and Treatment of Acute Vomiting in Dogs: Dogs 2-4 Months of Age:

Dosage

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/1 kg (1 mL/22 lb) of body weight once daily for up to 5 consecutive days.

Limitations

Cats (4 Months of Age and Older)

Indication

For Treatment of Vomiting in Cats 4 Months of Age and Older

Dosage

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/kg (0.1 mL/2.2 lb) of body weight once daily for up to 5 consecutive days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

Antiemetic used to prevent and treat vomiting (and motion sickness in dogs).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Use caution with severe liver disease.

Side Effects

Pain at injection site, lethargy, diarrhea.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Hair loss at application site (1) • Cat Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic

Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Behavior

Biting -aggression (1) • Dog Behavioral disorder (1) • Dog Anxiety (1) • Dog

Showing top 5 for Behavior.

Other

Bladder distension (1) • Cat Bilirubinuria (1) • Dog Basophilia (1) • Cat Bacterial skin infection NOS (1) • Dog Azotaemia (1) • Cat

Show more (20)

Ascites (1) • Cat Arthritis (1) • Cat Arrhythmia (1) • Cat Application site excoriation (1) • Cat Angioedema (1) • Dog Anaphylaxis (1) • Cat Anaphylactoid reaction (1) • Dog Anaemia NOS (1) • Dog Allergic reaction (1) • Dog Agitation (1) • Dog Agglutination test, positive (1) • Dog Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal tail posture (1) • Dog Abnormal radiograph finding (1) • Dog Abnormal posture NOS (1) • Dog Abnormal histology NOS (1) • Dog Abnormal cytology (1) • Cat Abdominal pain (1) • Dog Abdominal discomfort (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Persian, Male, 12.5 year, 4.4 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.44 mL per animal, Frequency: 6 per day • Reactions: Intentional misuse, Lack of efficacy - NOS, Death by euthanasia, Gait abnormality, Lumbar pain • Outcome: Euthanized

Report ID: USA-USFDACVM-2025-US-075165
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 12.50 Year
Weight: 4.400 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Injection
Dose: 0.44 mL per animal
Frequency: 6 per day

Reactions Reported:

Intentional misuse Lack of efficacy - NOS Death by euthanasia Gait abnormality Lumbar pain

Outcomes: Euthanized

Dog, Chihuahua, Male, 12 year, 3.084 kilogram • Drug: MSK, Tablet, Unknown • Reactions: Seizure NOS, Lateral recumbency, Unresponsive to stimuli, Bradycardia • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-075262
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 12.00 Year
Weight: 3.084 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Tablet

Reactions Reported:

Seizure NOS Lateral recumbency Unresponsive to stimuli Bradycardia

Outcomes: Recovered/Normal

Dog, Siberian Husky, Male, 9 year, 21.682 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 2.20 mL per animal • Reactions: Injection site lesion, Crust, Injection site ulcer, Injection site erythema, Injection site discharge NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-075214
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 21.682 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Injection
Dose: 2.20 mL per animal

Reactions Reported:

Injection site lesion Crust Injection site ulcer Injection site erythema Injection site discharge NOS

Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 15 year, 3.302 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Elevated symmetrical dimethylarginine, Elevated creatinine, Elevated serum alkaline phosphatase, Weight loss, Accidental exposure… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-075358
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 15.00 Year
Weight: 3.302 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Elevated symmetrical dimethylarginine Elevated creatinine Elevated serum alkaline phosphatase Weight loss Accidental exposure Anaemia NOS

Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 7 month, 3.08 kilogram • Drug: MSK, Unknown • Reactions: Fever, Cough, productive, Weight loss, Breathing difficulty, Abnormal radiograph finding… • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-075237
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 7.00 Month
Weight: 3.080 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Fever Cough, productive Weight loss Breathing difficulty Abnormal radiograph finding Pulmonary disorder NOS Tiredness (lethargy) Sedation Kidney atrophy Bilirubinuria Elevated mean corpuscular haemoglobin concentration Enlarged kidney Elevated mean corpuscular volume Eosinopenia Low serum alkaline phosphatase Neutropenia Discoloured urine Monocytosis Lymphopenia Elevated amylase Elevated alanine aminotransferase Low creatinine Hyponatremia Other abnormal test result NOS Elevated total bilirubin Hyperglycaemia Lymphocytosis Neutrophilia Leucocytosis NOS Basophilia

Outcomes: Recovered/Normal

Dog, ['Retriever - Golden', 'Beagle', 'Chow Chow'], Male, 11 year, 19.504 kilogram • Drug: MSK, Tablet, Oral • Reactions: Unsteady walking (ataxia), Vestibular disorder NOS, Weight loss, Head tilt - neurological disorder, Low vision… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-075189
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 11.00 Year
Weight: 19.504 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet

Reactions Reported:

Unsteady walking (ataxia) Vestibular disorder NOS Weight loss Head tilt - neurological disorder Low vision Urinary incontinence Unable to rise Urinary tract infection Polydipsia Horizontal nystagmus Generalised weakness Depression

Outcomes: Ongoing

Dog, Setter - Irish Red, Male, 9 year, 38 kilogram • Drug: MSK, Tablet, Oral, Dose: 80 Milligram per dose, Frequency: 24 per hour • Reactions: Inappetence, Elevated liver enzymes NOS, Tiredness (lethargy), Polydipsia, Polyuria… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-075441
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 38.000 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet
Dose: 80 Milligram per dose
Frequency: 24 per hour

Reactions Reported:

Inappetence Elevated liver enzymes NOS Tiredness (lethargy) Polydipsia Polyuria Icterus

Outcomes: Ongoing

Dog, Retriever - Labrador, Male, 11.08 year, 30.5 kilogram • Drug: MSK, Unknown • Reactions: Ear infection NOS, Loss of appetite, Nausea, Vomiting, Polycythaemia… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-074697
Serious AE: No
Treated For AE: No
Sex: Male
Age: 11.08 Year
Weight: 30.500 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Ear infection NOS Loss of appetite Nausea Vomiting Polycythaemia Elevated haemoglobin Increased percentage reticulocytes Elevated mean corpuscular volume Elevated alanine aminotransferase Elevated serum alkaline phosphatase Elevated gamma-glutamyl transferase Elevated cholesterol Hyperproteinaemia Elevated total bilirubin Elevated blood urea nitrogen Abnormal ultrasound finding Abnormal histology NOS Other abnormal test result NOS

Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

Overdose causes excessive drooling, lethargy, collapse due to low BP. Emergency care includes IV fluids, blood pressure support, and monitoring.

Storage & Handling

Store per label; protect injectable from light.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Maropitant Citrate

Data freshness

Evidence

Maropitant Citrate

Medication Snapshot

Maropitant Citrate

Indications / Uses

Administration / How To Give

Storage

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

How should this be stored?

Related Medications

Related Conditions

Source Transparency

Add to My Pet's Meds

Pet Owner Quick Guide

Quick Facts

Warnings / Contraindications

Adverse Reactions

Grouped by Body System

Most Reported Reactions

Storage & Handling

Documents

Owner handouts

Official label / PI

SPL

FOI

Maropitant Citrate Tablets

Maropitant Citrate Tablets

Dogs

Maropitant Citrate

Maropitant Citrate

Dogs

Cats

Maropitant Citrate Tablets

Maropitant Citrate Tablets

Dogs

Maropitant Citrate

Maropitant Citrate

Dogs (2-7 months of age)

Dogs (7 months of age and older)

Dogs (4 months of age and older)

Cerenia® Tablets

Cerenia® Tablets

Dogs (7 Months of Age and Older)

Dogs (4 Months of Age and Older)

Dogs (2-7 Months)

Cerenia® Injectable Solution

Cerenia® Injectable Solution

Dogs (2-4 Months of Age)

Dogs (4 Months of Age and Older)

Cats (4 Months of Age and Older)

FOI Summary oA 200-833 Approved January 12, 2026.pdf

FOI Summary oA 200-710 Approved December 5, 2025.pdf

FOI Summary oA 200-785 Approved June 17, 2024.pdf

FOI Summary oA 200-747 Approved March 31, 2023.pdf

UCM453543.pdf

UCM050060.pdf

UCM484493.pdf

UCM314823.pdf

UCM314825.pdf

ucm062313.pdf

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Change Log

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)

Maropitant Citrate Tablets • Chewable Tablets • Oral

Maropitant Citrate • Injectable Solution • Intravenous, Subcutaneous

Maropitant Citrate Tablets • Tablet • Oral

Maropitant Citrate • Tablet • Oral

Cerenia® Tablets • Tablet • Oral

Cerenia® Injectable Solution • Liquid (Solution) • Subcutaneous, Intravenous